Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • cadila

    Tag: Cadila

    You Searched For "cadila"
    Dr VG Somani DCGI releases IPA guidelines on Market Complaints.

    Dr VG Somani DCGI releases IPA guidelines on Market Complaints.

    Medical Dialogues Bureau2 March 2020 10:30 AM IST
    The guidelines were released at the recently concluded India Pharmaceutical Forum
    NPPA fixes retail price of 44 combo drugs including Metformin, Vildagliptin, Paracetamol; Details

    NPPA fixes retail price of 44 combo drugs including Metformin, Vildagliptin, Paracetamol; Details

    Farhat Nasim20 Dec 2019 11:55 AM IST
    New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the...
    Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

    Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

    Medical Dialogues Bureau12 Dec 2019 11:53 AM IST
    Ahmedabad: With the Novartis Blockbuster Vildagliptin going off patent, Zydus Cadila has taken made its move towards affordable diabetes care in India...
    Cadila Healthcare Moraiya plant gets USFDA warning letter for significant violations of CGMP

    Cadila Healthcare Moraiya plant gets USFDA warning letter for significant violations of CGMP

    Medical Dialogues Bureau16 Nov 2019 11:11 AM IST
    Cadila Healthcare failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilise equipment and utensils at...
    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    Medical Dialogues Bureau7 Nov 2019 4:20 PM IST
    Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug...
    Cadila Healthcare gets EIR from USFDA for Baddi facility

    Cadila Healthcare gets EIR from USFDA for Baddi facility

    Medical Dialogues Bureau1 Nov 2019 2:11 PM IST
    New Delhi: Drug firm Cadila Healthcare on Thursday said its Baddi facility in Himachal Pradesh has received establishment inspection report (EIR) from...
    Cadila Healthcare arm gets USFDA nod for Haloperidol Decanoate injection to treat schizophrenia

    Cadila Healthcare arm gets USFDA nod for Haloperidol Decanoate injection to treat schizophrenia

    Medical Dialogues Bureau25 Oct 2019 11:32 AM IST
    Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome, Cadila Healthcare...
    Cadila Healthcare largest API manufacturing site clears USFDA inspection

    Cadila Healthcare largest API manufacturing site clears USFDA inspection

    Medical Dialogues Bureau12 Oct 2019 11:41 AM IST
    The US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from...
    Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

    Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol

    Medical Dialogues Bureau10 Oct 2019 11:34 AM IST
    Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets,...
    Cadila Healthcare to sell right of cholesterol-lowering drug Zypitamag for Rs 49 crore

    Cadila Healthcare to sell right of cholesterol-lowering drug Zypitamag for Rs 49 crore

    Farhat Nasim1 Oct 2019 2:13 PM IST
    The company has entered into an asset purchase agreement to sell its right, title and interest in Zypitamag, along with applicable registrations and...
    Cadila Pharma bags ObserveNow Future of Workplace Award among 50 others in fray

    Cadila Pharma bags ObserveNow Future of Workplace Award among 50 others in fray

    Medical Dialogues Bureau16 Sept 2019 9:25 AM IST
    "The selection was made on the basis of the technologies used in the company, HR policies, and initiatives taken to make the organization an...
    Cadila Healthcare Ankleshwar facility successfully completes USFDA inspection

    Cadila Healthcare Ankleshwar facility successfully completes USFDA inspection

    Medical Dialogues Bureau1 Aug 2019 9:25 AM IST
    "The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok